Kono S, Rao J S, Bruner J M, Sawaya R
Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Houston.
J Neuropathol Exp Neurol. 1994 May;53(3):256-62. doi: 10.1097/00005072-199405000-00006.
We investigated the immunohistochemical localization of plasminogen activator inhibitor type 1 (PAI-1) in surgical specimens of 41 human intracranial tumors. Malignant tumors (7 glioblastoma multiforme, 5 anaplastic gliomas, 4 malignant meningiomas, and 9 metastatic tumors) showed consistently stronger PAI-1 immunohistoreactivity than benign or low-grade tumors (5 low-grade gliomas, 8 benign meningiomas, and 3 Schwannomas). Strong PAI-1 positivity was confined to glomeruloid-shaped proliferative vessels seen in high-grade gliomas and metastatic tumors. Blood vessels near necrotic foci and some zones of necrosis also showed strong PAI-1 positivity. PAI-1 localizes in the vascular basement membrane and perivascular connective tissue, while endothelial cells themselves show weak positivity. None of the specimens showed PAI-1 reactivity within the tumor cells per se. Localization of PAI-1 in proliferating vessels suggests that PAI-1 may be involved in angiogenesis.
我们研究了41例人类颅内肿瘤手术标本中1型纤溶酶原激活物抑制剂(PAI-1)的免疫组化定位。恶性肿瘤(7例多形性胶质母细胞瘤、5例间变性胶质瘤、4例恶性脑膜瘤和9例转移瘤)的PAI-1免疫反应性始终比良性或低级别肿瘤(5例低级别胶质瘤、8例良性脑膜瘤和3例神经鞘瘤)更强。强烈的PAI-1阳性局限于高级别胶质瘤和转移瘤中所见的肾小球样增生血管。坏死灶附近的血管和一些坏死区域也显示出强烈的PAI-1阳性。PAI-1定位于血管基底膜和血管周围结缔组织,而内皮细胞本身显示弱阳性。所有标本的肿瘤细胞本身均未显示PAI-1反应性。PAI-1在增生血管中的定位表明PAI-1可能参与血管生成。